Oct 14, 2022
Aducanumab (brand name Aduhelm) drew headlines when it was approved by the FDA in 2021 against the recommendations of the FDA advisory committee. Today it's almost commercially dead. On this episode are joined by P4 student Ise Brockmann to dive into aducanumab's story.
email: econrxpodcast@gmail.com
Twitter/Instagram:...
Apr 21, 2022
Capping patient out-of-pocket costs for insulin has been a popular move for legislators, most recently by the US House. On this episode we weigh the Pros, Cons, and viral reactions to this move including lowering vs. shifting costs, ADA guidelines, and political theater.
email: econrxpodcast@gmail.com
Twitter/Instagram:...